These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Occurrence of cefotaxime-resistant Enterobacter during therapy of cardiac surgery patients. Weinstein RA Chemioterapia; 1985 Feb; 4(1):110-2. PubMed ID: 3986939 [TBL] [Abstract][Full Text] [Related]
6. [Beta-lactam resistance in aquatic Enterobacter cloacae strains using phenotypic and genotypic criteria]. Lazăr V; Cernat R; Balotescu C; Cotar A; Coipan E; Cojocaru C Bacteriol Virusol Parazitol Epidemiol; 2002; 47(3-4):185-91. PubMed ID: 15085610 [TBL] [Abstract][Full Text] [Related]
7. Broad-spectrum beta-lactam resistance in Enterobacter: emergence during treatment and mechanisms of resistance. Olson B; Weinstein RA; Nathan C; Kabins SA J Antimicrob Chemother; 1983 Apr; 11(4):299-310. PubMed ID: 6602122 [TBL] [Abstract][Full Text] [Related]
8. [Treatment with a cefotaxime-fosfomycin combination of staphylococcal or enterobacterial meningitis in adults]. Portier H; Armengaud M; Becq-Giraudon B; Bousser J; Desbordes JM; Duez JM; Kazmierczak A; Korinek AM; Laisne MJ; Pangon B Presse Med; 1987 Dec; 16(43):2161-6. PubMed ID: 2963304 [TBL] [Abstract][Full Text] [Related]
9. Emergence of resistance to ceftazidime during therapy for Enterobacter cloacae infections. Quinn JP; DiVincenzo CA; Foster J J Infect Dis; 1987 May; 155(5):942-7. PubMed ID: 3549922 [TBL] [Abstract][Full Text] [Related]
10. Cefotaxime and aminoglycoside treatment of meningitis caused by gram-negative enteric organisms. Kaplan SL; Patrick CC Pediatr Infect Dis J; 1990 Nov; 9(11):810-4. PubMed ID: 2263430 [TBL] [Abstract][Full Text] [Related]
11. Five years of cefotaxime use in a neonatal intensive care unit. Spritzer R; vd Kamp HJ; Dzoljic G; Sauer PJ Pediatr Infect Dis J; 1990 Feb; 9(2):92-6. PubMed ID: 2179846 [TBL] [Abstract][Full Text] [Related]
12. Effectiveness of cefotaxime in gram-negative meningitis. LeFrock JL; Molavi A; Smith B; Black P; Rosenberg M; Rolston K; Brodner R; Chandrasekar P; Henao L; Kannangara DW Neurosurgery; 1984 Nov; 15(5):679-82. PubMed ID: 6095133 [TBL] [Abstract][Full Text] [Related]
15. [Development of cefotaxime resistance during treatment]. Søgaard P Ugeskr Laeger; 1986 Jan; 148(5):260-1. PubMed ID: 3952856 [No Abstract] [Full Text] [Related]
16. Gentamicin vs cefotaxime for therapy of neonatal sepsis. Relationship to drug resistance. Bryan CS; John JF; Pai MS; Austin TL Am J Dis Child; 1985 Nov; 139(11):1086-9. PubMed ID: 3904403 [TBL] [Abstract][Full Text] [Related]
17. Clinical and microbiologic characteristics of cefotaxime-non-susceptible Enterobacteriaceae bacteremia: a case control study. Noguchi T; Matsumura Y; Yamamoto M; Nagao M; Takakura S; Ichiyama S BMC Infect Dis; 2017 Jan; 17(1):44. PubMed ID: 28061869 [TBL] [Abstract][Full Text] [Related]
18. The origin, by mutation, of high level resistance to ceftazidime and cefotaxime in a clinical isolate of Enterobacter cloacae. Blahová J; Lesická-Hupková M; Králiková K; Krcméry V; Mikovicová A J Chemother; 1996 Aug; 8(4):266-9. PubMed ID: 8873831 [TBL] [Abstract][Full Text] [Related]
19. Chromosomal beta-lactamase expression and antibiotic resistance in Enterobacter cloacae. Yang YJ; Livermore DM; Williams RJ J Med Microbiol; 1988 Mar; 25(3):227-33. PubMed ID: 3258037 [TBL] [Abstract][Full Text] [Related]
20. [Enterobacter cloacae and E. aerogenes septicemia: emergence of resistant variants (derepressed cephalosporinase) during treatment with third-generation cephalosporins]. Nauciel C; Philippon A; Ronco E; Pilliot J; Guenounou M; Paul G; Brunel D; Outin HD Presse Med; 1985 Mar; 14(12):673-6. PubMed ID: 3157961 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]